Evidence map›Paper›PMID 40788622›Full record

ArticleInternational endodontic journal2025

PFKFB3-Inhibitor 3PO-Mediated Glycolytic Reprogramming Promotes Inflammatory Dental Pulp Repair: An In Vitro and In Vivo Study.

Yanqiang Zhao, Yuqing Peng, Dan Wang, Lixin Zhang, Yijia Qiu, Jingyi Cui, Fei Xie, Ningxin Zhu, Man Qin, Yuanyuan Wang

Abstract read
In one paragraph

Article in International endodontic journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yanqiang ZhaoDepartment of Pediatric Dentistry, School and Hospital of Stomatology, Peking University, Beijing, China.ORCID https://orcid.org/0009-0002-9215-0702
Yuqing PengDepartment of Pediatric Dentistry, School and Hospital of Stomatology, Peking University, Beijing, China.ORCID https://orcid.org/0000-0001-8201-143X
Dan WangDepartment of Pediatric Dentistry, School and Hospital of Stomatology, Peking University, Beijing, China.
Lixin ZhangDepartment of Pediatric Dentistry, School and Hospital of Stomatology, Peking University, Beijing, China.
Yijia QiuDepartment of Pediatric Dentistry, School and Hospital of Stomatology, Peking University, Beijing, China.
Jingyi CuiDepartment of Pediatric Dentistry, School and Hospital of Stomatology, Peking University, Beijing, China.ORCID https://orcid.org/0009-0004-2178-9714
Fei XieDepartment of Pediatric Dentistry, School and Hospital of Stomatology, Peking University, Beijing, China.ORCID https://orcid.org/0000-0002-8764-8824
Ningxin ZhuDepartment of Pediatric Dentistry, School and Hospital of Stomatology, Peking University, Beijing, China.
Man QinDepartment of Pediatric Dentistry, School and Hospital of Stomatology, Peking University, Beijing, China.ORCID https://orcid.org/0000-0001-5791-3319
Yuanyuan WangDepartment of Pediatric Dentistry, School and Hospital of Stomatology, Peking University, Beijing, China.ORCID https://orcid.org/0000-0003-1126-1639

Funding

Beijing Natural Science Foundation 7222222Beijing Natural Science Foundation 7244445
6 · The paper itself

Abstract

aimThis study explores the role of PFKFB3 in pulpitis and its potential as a therapeutic target by modulating glycolytic reprogramming in dental pulp stem cells (DPSCs). Pulpitis, a common inflammatory disease, causes long-term damage to dental structures. Recent evidence suggests that metabolic reprogramming can modulate inflammatory responses and promote tissue repair. This study aims to investigate the anti-inflammatory and reparative effects of glycolysis inhibitors on inflamed dental pulp through in vivo and in vitro experiments. METHODOLOGY: In vitro, hDPSCs were stimulated with lipopolysaccharide (LPS) (1 μg/mL, 3 h) to mimic pulpitis. The effects of the PFKFB3 inhibitor 3PO (10 μM) and siRNA targeting PFKFB3 (50 nM) on glycolysis were assessed using Seahorse analysis, while their impacts on inflammation were evaluated via ELISA and qRT-PCR. A co-culture of DPSCs and macrophages was used to study 3PO's effects on inflammation interactions and glycolytic reprogramming of the inflammatory microenvironment. The influences of 3PO on odontogenic differentiation were examined through qRT-PCR, Western blotting, ALP staining and ARS staining. The related signalling pathways were validated through Western blot (WB) experiments. An SD rat model was employed to validate the in vivo efficacy of 3PO@GelMA pulp capping, and HE staining and immunohistochemistry were used to evaluate the degree of pulp inflammation and reparative dentine formation.

resultsIn vitro, LPS elevated glycolytic activity and inflammatory factors (IL-6, IL-1β, TNF-α) in DPSCs. 3PO and si-PFKFB3 mitigated these factors and promoted odontogenic differentiation, evidenced by increased DSPP and ALP expression. Metabolic reprogramming mediated by 3PO and si-PFKFB3, as assessed by Seahorse XF analysis, indicated a shift from glycolysis to oxidative phosphorylation. Additionally, 3PO induced metabolic reprogramming of the co-culture system, reduced the levels of pro-inflammatory cytokines, and promoted the polarisation of macrophages towards the M2 phenotype. PFKFB3 inhibition activated the AMPK/SIRT1/PGC-1α/NF-κB and AMPK/mTOR/NF-κB signalling pathways. In vivo, in the rat pulpitis model, 3PO@GelMA hydrogel application resulted in significantly decreased IL-6 and increased DSPP expression compared to the LPS group (p < 0.001), accompanied by reduced inflammation and enhanced reparative dentine formation.

conclusionThe PFKFB3 inhibitor 3PO reduces inflammation and promotes reparative dentine formation in pulpitis via metabolic reprogramming and specific signalling pathways, offering a new therapeutic strategy.

Indexed as

Dental PulpGlycolysisPhosphofructokinase-2PulpitisAnimalsCell DifferentiationCells, CulturedCoculture TechniquesHumansInflammationLipopolysaccharidesRatsStem CellsLipopolysaccharidesPFKFB3 protein, humanPhosphofructokinase-23POanimal modelglycolytic reprogrammingPFKFB3pulpitis

Identifiers

PMID40788622
PMCPMC12620336

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.